Invivo Therapeutics Holdings Stock Current Valuation
Valuation analysis of InVivo Therapeutics helps investors to measure InVivo Therapeutics' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
InVivo Therapeutics Holdings Company Current Valuation Analysis
InVivo Therapeutics' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current InVivo Therapeutics Current Valuation | (7.59 M) |
Most of InVivo Therapeutics' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, InVivo Therapeutics Holdings is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
CompetitionIn accordance with the recently published financial statements, InVivo Therapeutics Holdings has a Current Valuation of (7.59 Million). This is 100.05% lower than that of the Health Care Equipment & Supplies sector and 100.16% lower than that of the Health Care industry. The current valuation for all United States stocks is 100.05% higher than that of the company.
InVivo Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses InVivo Therapeutics' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of InVivo Therapeutics could also be used in its relative valuation, which is a method of valuing InVivo Therapeutics by comparing valuation metrics of similar companies.InVivo Therapeutics is currently under evaluation in current valuation category among its peers.
InVivo Fundamentals
| Return On Equity | -0.98 | |||
| Return On Asset | -0.54 | |||
| Current Valuation | (7.59 M) | |||
| Shares Outstanding | 3.11 M | |||
| Shares Owned By Insiders | 0.02 % | |||
| Shares Owned By Institutions | 3.44 % | |||
| Number Of Shares Shorted | 17.63 K | |||
| Price To Earning | (1.90) X | |||
| Price To Book | 0.1 X | |||
| EBITDA | (9.8 M) | |||
| Net Income | (9.33 M) | |||
| Cash And Equivalents | 13.03 M | |||
| Cash Per Share | 9.36 X | |||
| Total Debt | 949 K | |||
| Debt To Equity | 0.09 % | |||
| Current Ratio | 5.64 X | |||
| Book Value Per Share | 2.87 X | |||
| Cash Flow From Operations | (10.13 M) | |||
| Short Ratio | 0.91 X | |||
| Earnings Per Share | (3.28) X | |||
| Target Price | 37.5 | |||
| Beta | 0.66 | |||
| Market Capitalization | 995.92 K | |||
| Total Asset | 18.82 M | |||
| Retained Earnings | (248.62 M) | |||
| Working Capital | 15.13 M | |||
| Current Asset | 20.74 M | |||
| Current Liabilities | 3.31 M | |||
| Z Score | -18.62 | |||
| Net Asset | 18.82 M |
Thematic Opportunities
Explore Investment Opportunities
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Other Consideration for investing in InVivo Stock
If you are still planning to invest in InVivo Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the InVivo Therapeutics' history and understand the potential risks before investing.
| CEOs Directory Screen CEOs from public companies around the world | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm |